‘The Next Tulip Mania?’ – Fidelity, Gurnet, Biogen Put A Lens To Funding, Valuations
In 2020, Panelists Predicted Bust
Venture capital funding for biotechs remains aplenty even as listed companies’ stock prices drop. Biogen’s Papadopoulos, Fidelity’s Kaul and Gurnet’s and ex-Sanofi Viehbacher deliberate on whether there is a valuation disconnect and if this is the next "tulip mania."
You may also be interested in...
Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead
Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO Robert Coleman tells Scrip.
IPO Update: Mid-Year Average Return Deceptively Positive In Down Market
The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities.
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.